Burden of Disease in COPD and Asthma Stratified by Eosinophils Levels
Asthma is a chronic lung disease affecting people of all ages, it is caused by inflammation and muscle tightening around the airways, which makes it harder to breathe. Chronic obstructive pulmonary disease (COPD) is a common lung disease which produces a restricted airflow; smoking and air pollution are the most common causes for this disease.
Evidence suggests that blood eosinophil levels (EOS) can influence the response to therapy in both asthma and COPD and predict future exacerbation outcomes.
Given this information, our Real-World Evidence (RWE) experts conducted two independent studies to characterize asthma and COPD burden stratified by EOS levels. Data was extracted from the UK Biobank, a large-scale biomedical database containing health information from half a million UK participants.
Our team presented the results of these studies through two posters during the ERS International Congress. View the posters below and discover the impact of raised EOS in asthma and COPD burden.
Click below to download the full-screen versions.
Learn more about our Real-World Solutions to leverage and interpret data across the entire healthcare ecosystem.